Literature DB >> 22807084

Genetics and epigenetics of hepatoblastoma.

Gail E Tomlinson1, Roland Kappler.   

Abstract

A number of unique genetic features are observed in hepatoblastoma that have provided insights into the origins of hepatoblastoma. Hallmark cytogenetic changes in hepatoblastoma include the acquisition of additional copies of whole chromosomes and a recurring unbalanced translocation involving 1q. Genetic syndromes are associated with approximately 15% of hepatoblastoma and the understanding and recognition of these syndromes will be important in determining future surveillance studies needed to prevent additional cancers in survivors as well as in some case guide the care of family members. This article will review the genetic changes, both germ line and acquired, that are recurring events in hepatoblastoma, with emphasis on how these genetic changes could work together with other developmental factors and influence cancer predisposition, tumor growth, as well as aid in prognosis. Tumor-specific signatures based on transcriptional or epigenetic alterations will be reviewed that might be used in the future to better diagnose and subtype the disease as well as predict prognosis and response to therapy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22807084     DOI: 10.1002/pbc.24213

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  26 in total

1.  Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.

Authors:  Alexander Beck; Corinna Eberherr; Michaela Hagemann; Stefano Cairo; Beate Häberle; Christian Vokuhl; Dietrich von Schweinitz; Roland Kappler
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

2.  What do we know about the etiology of hepatoblastoma?

Authors:  Lucie M Turcotte; Logan G Spector
Journal:  Hepat Oncol       Date:  2013-12-20

Review 3.  Magnetic resonance imaging of primary pediatric liver tumors.

Authors:  Brian S Pugmire; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2016-05-26

4.  The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.

Authors:  Kelly A Duffy; Matthew A Deardorff; Jennifer M Kalish
Journal:  Am J Med Genet A       Date:  2017-02-04       Impact factor: 2.802

Review 5.  Children's Oncology Group's 2013 blueprint for research: rare tumors.

Authors:  Carlos Rodriguez-Galindo; Mark Krailo; Lindsay Frazier; Murali Chintagumpala; James Amatruda; Howard Katzenstein; Marcio Malogolowkin; Logan Spector; Farzana Pashankar; Rebecka Meyers; Gail Tomlinson
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

6.  Genomic Profiling Reveals Unique Molecular Alterations in Hepatoblastomas and Adjacent Hepatocellular Carcinomas in B6C3F1 Mice.

Authors:  Sachin Bhusari; Arun R Pandiri; Hiroaki Nagai; Yu Wang; Julie Foley; Hue-Hua L Hong; Thai-Vu Ton; Michael DeVito; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; David E Malarkey; Michelle J Hooth; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-08-18       Impact factor: 1.902

7.  Genome-wide analysis of DNA methylation in hepatoblastoma tissues.

Authors:  Ximao Cui; Baihui Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

Review 8.  Surgical Pathology Diagnostic Pitfalls of Hepatoblastoma.

Authors:  Finn Morgan Auld; Consolato M Sergi
Journal:  Int J Surg Pathol       Date:  2022-01-20       Impact factor: 1.358

9.  Genome-wide analysis of long noncoding RNA (lncRNA) expression in hepatoblastoma tissues.

Authors:  Rui Dong; Deshui Jia; Ping Xue; Ximao Cui; Kai Li; Shan Zheng; Xianghuo He; Kuiran Dong
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

10.  Comprehensive analyses of imprinted differentially methylated regions reveal epigenetic and genetic characteristics in hepatoblastoma.

Authors:  Janette Mareska Rumbajan; Toshiyuki Maeda; Ryota Souzaki; Kazumasa Mitsui; Ken Higashimoto; Kazuhiko Nakabayashi; Hitomi Yatsuki; Kenichi Nishioka; Ryoko Harada; Shigehisa Aoki; Kenichi Kohashi; Yoshinao Oda; Kenichiro Hata; Tsutomu Saji; Tomoaki Taguchi; Tatsuro Tajiri; Hidenobu Soejima; Keiichiro Joh
Journal:  BMC Cancer       Date:  2013-12-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.